Harold Bernstein, President, R&D & CMO at Maze Therapeutics, Inc. (MAZE), sold 15,000 shares at $29.24 ($442K) on 2026-04-01, disclosed to the SEC on 2026-04-02.
Scheduled sale ($442k) by President, R&D & CMO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $29.24 | 11,352 | $332K | 75.1% |
| 2 | $30.06 | 3,348 | $101K | 22.8% |
| 3 | $31.07 | 300 | $9K | 2.1% |
| Total | $29.46 avg | 15,000 | $442K | 100% |
| Filing → |
| MAZE | SELL | 2026-09-04 | $270K | — | Filing → |
| MAZE | SELL | 2026-09-03 | $426K | — | Filing → |
| MAZE | SELL | 2026-08-14 | $446K | — | Filing → |